

November 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2013-002306-31/ Novartis Protocol ID CLCZ696A2320E1

An open-label, long term (52 week) extension study to evaluate the safety, tolerability, and efficacy of treatment with LCZ696 monotherapy and LCZ696 in combination with amlodipine in patients with essential hypertension

Trial CLCZ696A2320E1 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.